BioCentury
ARTICLE | Financial News

Eye infection company Okogen raises $10M series A

February 27, 2018 1:31 PM UTC

Ocular infection company Okogen Inc. (San Diego, Calif.) raised $10 million in a series A round from Brandon Capital through the VC's Medical Research Commercialisation Fund.

Okogen plans to start a Phase II trial of lead candidate OKG-0301 to treat viral conjunctivitis this year. It is an ophthalmic formulation of ranpirnase, a ribonuclease with broad-spectrum antiviral properties...